Theracos Valuation, Funding & Investors

Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Planet, Investments, and others. The majority of its revenue is generated from the planet segment. The geographical segments are UAE, Other GCC countries, and Other countries.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

AIRNA is a biotechnology company, based in Cambridge, Massachusetts, and Tübingen, Germany, that develops RNA editing therapeutics through its proprietary RESTORE+ platform. The platform makes precise edits to RNA to introduce beneficial genetic variants or repair disease-causing mutations, producing re-administrable medicines with simplified manufacturing compared to gene therapies. Its lead candidate targets alpha-1 antitrypsin deficiency, a genetic disorder that causes lung and liver disease, with additional programs planned in cardiometabolic conditions.

Ildong Pharmaceutical Co Ltd is a Korean company which is engaged in manufacturing pharmaceutical products. Its product portfolio includes generic drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, antihistamines, antipyretics, analgesics, respiratory medications, endocrine medications, psycho-neurological medications, dermatological medications, urologic medications, antibiotics and others. The company also provides raw materials such as synthesizes, probiotics and others.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

GC Corp focuses on healthcare-related activities, including the diagnosis, prevention, treatment, and management of diseases.

Lycia Therapeutics is a South San Francisco-based biotechnology firm advancing lysosomal targeting chimeras platform to degrade disease-causing extracellular proteins. Its LYTAC technology addresses targets inaccessible to traditional drugs, developing therapies for neurodegenerative disorders, cancer, and autoimmune diseases. Founded in 2020, the company raised significant venture funding from investors like Versant Ventures and The Column Group.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Kumquat Biosciences is a San Diego-headquartered biopharmaceutical company advancing targeted cancer therapies through small-molecule inhibitors. Its pipeline targets KRAS mutations and DNA damage response pathways, with lead candidates entering Phase I trials for solid tumors. The firm leverages structure-based drug design and proprietary assays to develop orally bioavailable compounds. Kumquat Biosciences collaborates with academic institutions in California, focusing on precision oncology for lung, pancreatic, and colorectal cancers.

Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self-Treatment, and Dermocosmetic care. Its operating segments include Medicines, Parapharmaceuticals, and Services.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.